Search

Your search keyword '"Ali, H.R. (Hamid Raza)"' showing total 5 results
Start Over Author "Ali, H.R. (Hamid Raza)"
5 results on '"Ali, H.R. (Hamid Raza)"'

1. Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation

Author

Abubakar, M. (Mustapha), Chang-Claude, J. (Jenny), Ali, H.R. (Hamid Raza), Chatterjee, N. (Nilanjan), Coulson, P. (Penny), Daley, F. (Frances), Blows, F. (Fiona), Benítez, J. (Javier), Milne, R.L. (Roger), Brenner, H. (Hermann), Stegmaier, C. (Christa), Mannermaa, A. (Arto), Rudolph, A. (Anja), Sinn, P. (Peter), Couch, F.J. (Fergus J.), Devilee, P. (Peter), Tollenaar, R.A.E.M. (Rob), Seynaeve, C.M. (Caroline), Figueroa, J.D. (Jonine), Lissowska, J. (Jolanta), Hewitt, S.M. (Stephen), Hooning, M.J. (Maartje), Hollestelle, A. (Antoinette), Foekens, R. (Renée), Koppert, L.B. (Linetta), Bolla, M.K. (Manjeet K.), Wang, Q. (Qin), Jones, M.E. (Michael E.), Schoemaker, M.J. (Minouk J.), Keeman, J.N., Easton, D.F. (Douglas), Swerdlow, A.J. (Anthony ), Sherman, M.E. (Mark), Schmidt, M.K. (Marjanka), Pharoah, P.D. (Paul D.), García-Closas, M. (Montserrat), Abubakar, M. (Mustapha), Chang-Claude, J. (Jenny), Ali, H.R. (Hamid Raza), Chatterjee, N. (Nilanjan), Coulson, P. (Penny), Daley, F. (Frances), Blows, F. (Fiona), Benítez, J. (Javier), Milne, R.L. (Roger), Brenner, H. (Hermann), Stegmaier, C. (Christa), Mannermaa, A. (Arto), Rudolph, A. (Anja), Sinn, P. (Peter), Couch, F.J. (Fergus J.), Devilee, P. (Peter), Tollenaar, R.A.E.M. (Rob), Seynaeve, C.M. (Caroline), Figueroa, J.D. (Jonine), Lissowska, J. (Jolanta), Hewitt, S.M. (Stephen), Hooning, M.J. (Maartje), Hollestelle, A. (Antoinette), Foekens, R. (Renée), Koppert, L.B. (Linetta), Bolla, M.K. (Manjeet K.), Wang, Q. (Qin), Jones, M.E. (Michael E.), Schoemaker, M.J. (Minouk J.), Keeman, J.N., Easton, D.F. (Douglas), Swerdlow, A.J. (Anthony ), Sherman, M.E. (Mark), Schmidt, M.K. (Marjanka), Pharoah, P.D. (Paul D.), and García-Closas, M. (Montserrat)

Abstract

Limited epidemiological evidence suggests that the etiology of hormone receptor positive (HR+) breast cancer may differ by levels of histologic grade and proliferation. We pooled risk factor and pathology data on 5,905 HR+ breast cancer cases and 26,281 controls from 11 epidemiological studies. Proliferation was determined by centralized automated measures of KI67 in tissue microarrays. Odds ratios (OR), 95% confidence intervals (CI) and p-values for case-case and case-control comparisons for risk factors in relation to levels of grade and quartiles (Q1-Q4) of KI67 were estimated using polytomous logistic regression models. Case-case comparisons showed associations between nulliparity and high KI67 [OR (95% CI) for Q4 vs. Q1=1.54 (1.22, 1.95)]; obesity and high grade [grade 3 vs. 1=1.68 (1.31, 2.16)] and current use of combined hormone therapy (HT) and low grade [grade 3 vs. 1=0.27 (0.16, 0.44)] tumors. In case-control comparisons, nulliparity was associated with elevated risk of tumors with high but not low levels of proliferation [1.43 (1.14, 1.81) for KI67 Q4 vs. 0.83 (0.60, 1.14) for KI67 Q1]; obesity among women ≥50 years with high but not low grade tumors [1.55 (1.17, 2.06) for grade 3 vs. 0.88 (0.66, 1.16) for grade 1] and HT with low but not high grade tumors [3.07 (2.22, 4.23) for grade 1 vs. 0.85 (0.55, 1.30) for grade 3]. Menarcheal age and family history were similarly associated with HR+ tumors of different grade or KI67 levels. These findings provide insights into the etiologic heterogeneity of HR+ tumors.

Published
2018
Full Text
View/download PDF

2. TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer

Author

Fagerholm, R. (Rainer), Khan, S. (Sofia), Schmidt, M.K. (Marjanka), García-Closas, M. (Montserrat), Heikkilä, P. (Päivi), Saarela, J. (Jani), Beesley, J. (Jonathan), Jamshidi, M. (Maral), Aittomäki, K. (Kristiina), Liu, J. (Jianjun), Ali, H.R. (Hamid Raza), Andrulis, I.L. (Irene), Beckmann, M.W. (Matthias), Behrens, T.W. (Timothy), Blows, F.M. (Fiona M.), Brenner, H. (Hermann), Chang-Claude, J. (Jenny), Couch, F.J. (Fergus), Czene, K. (Kamila), Fasching, P.A. (Peter), Figueroa, J.D. (Jonine), Floris, O.A.M., Glendon, G. (Gord), Guo, Q. (Qi), Hll, P. (Per), Hallberg, E. (Emily), Hamann, U. (Ute), Holleczek, B. (B.), Hooning, M.J. (Maartje), Hopper, J.L. (John), Jager, A. (Agnes), Kabisch, M. (Maria), Keeman, J.N., Kosma, V-M. (Veli-Matti), Lambrechts, D. (Diether), Lindblom, A. (Annika), Mannermaa, A. (Arto), Margolin, S. (Sara), Provenzano, E. (Elena), Shah, M. (Mitul), Southey, M.C. (Melissa), Dennis, J. (Joe), Lush, M. (Michael), Michailidou, K. (Kyriaki), Wang, Q. (Qin), Bolla, M.K. (Manjeet K.), Dunning, A.M. (Alison), Easton, D.F. (Douglas), Pharoah, P.D.P. (Paul), Chenevix-Trench, G. (Georgia), Blomqvist, C. (Carl), Nevanlinna, H. (Heli), Fagerholm, R. (Rainer), Khan, S. (Sofia), Schmidt, M.K. (Marjanka), García-Closas, M. (Montserrat), Heikkilä, P. (Päivi), Saarela, J. (Jani), Beesley, J. (Jonathan), Jamshidi, M. (Maral), Aittomäki, K. (Kristiina), Liu, J. (Jianjun), Ali, H.R. (Hamid Raza), Andrulis, I.L. (Irene), Beckmann, M.W. (Matthias), Behrens, T.W. (Timothy), Blows, F.M. (Fiona M.), Brenner, H. (Hermann), Chang-Claude, J. (Jenny), Couch, F.J. (Fergus), Czene, K. (Kamila), Fasching, P.A. (Peter), Figueroa, J.D. (Jonine), Floris, O.A.M., Glendon, G. (Gord), Guo, Q. (Qi), Hll, P. (Per), Hallberg, E. (Emily), Hamann, U. (Ute), Holleczek, B. (B.), Hooning, M.J. (Maartje), Hopper, J.L. (John), Jager, A. (Agnes), Kabisch, M. (Maria), Keeman, J.N., Kosma, V-M. (Veli-Matti), Lambrechts, D. (Diether), Lindblom, A. (Annika), Mannermaa, A. (Arto), Margolin, S. (Sara), Provenzano, E. (Elena), Shah, M. (Mitul), Southey, M.C. (Melissa), Dennis, J. (Joe), Lush, M. (Michael), Michailidou, K. (Kyriaki), Wang, Q. (Qin), Bolla, M.K. (Manjeet K.), Dunning, A.M. (Alison), Easton, D.F. (Douglas), Pharoah, P.D.P. (Paul), Chenevix-Trench, G. (Georgia), Blomqvist, C. (Carl), and Nevanlinna, H. (Heli)

Abstract

TP53 overexpression is indicative of somatic TP53 mutations and associates with aggressive tumors and poor prognosis in breast cancer. We utilized a twostage SNP association study to detect variants associated with breast cancer survival in a TP53-dependent manner. Initially, a genome-wide study (n = 575 cases) was conducted to discover candidate SNPs for genotyping and validation in the Breast Cancer Association Consortium (BCAC). The SNPs were then tested for interaction with tumor TP53 status (n = 4,610) and anthracycline treatment (n = 17,828). For SNPs interacting with anthracycline treatment, siRNA knockdown experiments were carried out to validate candidate genes. In the test for interaction between SNP genotype and TP53 status, we identified one locus, represented by rs10916264 (p(interaction) = 3.44 × 10-5; FDR-adjusted p = 0.0011) in estrogen receptor (ER) positive cases. The rs10916264 AA genotype associated with worse survival among cases with ER-positive, TP53-positive tumors (hazard ratio [HR] 2.36, 95% confidence interval [C.I] 1.45-3.82). This is a cis-eQTL locus for FBXO28 and TP53BP2; expression levels of these genes were associated with patient survival specifically in ER-positive, TP53-mutated tumors. Additionally, the SNP rs798755 was associated with survival in interaction with anthracycline treatment (p(interaction) = 9.57 × 10-5, FDR-adjusted p = 0.0130). RNAi-based depletion of a predicted regulatory target gene, FAM53A, indicated that this gene can modulate doxorubicin sensitivity in breast cancer cell lines. If confirmed in independent data sets, these results may be of clinical relevance in the development of prognostic and predictive marker panels for breast cancer.

Published
2017
Full Text
View/download PDF

3. Prognostic value of automated KI67 scoring in breast cancer: A centralised evaluation of 8088 patients from 10 study groups

Author

Abubakar, M. (Mustapha), Orr, N. (Nick), Daley, F. (Frances), Coulson, P. (Penny), Ali, H.R. (Hamid Raza), Blows, F. (Fiona), Benítez, J. (Javier), Milne, R.L. (Roger), Brenner, H. (Hermann), Stegmaier, C. (Christa), Mannermaa, A. (Arto), Chang-Claude, J. (Jenny), Rudolph, A. (Anja), Sinn, P. (Peter), Couch, F.J. (Fergus), Devilee, P. (Peter), Tollenaar, R.A.E.M. (Rob), Seynaeve, C.M. (Caroline), Figueroa, J.D. (Jonine), Sherman, M.E. (Mark), Lissowska, J. (Jolanta), Hewitt, S.M. (Stephen), Eccles, D. (Diana), Hooning, M.J. (Maartje), Hollestelle, A. (Antoinette), Martens, J.W.M. (John), Deurzen, C.H.M. (Carolien) van, Investigators, C.F. (kConFab), Bolla, M.K. (Manjeet K.), Wang, Q. (Qin), Jones, M. (Michael), Schoemaker, M. (Minouk), Wesseling, J. (Jelle), Leeuwen, F.E. (Flora) van, Veer, L.J. (Laura) van 't, Easton, D.F. (Douglas), Swerdlow, A.J. (Anthony ), Dowsett, M. (Mitch), Pharoah, P.D.P. (Paul), Schmidt, M.K. (Marjanka), García-Closas, M. (Montserrat), Abubakar, M. (Mustapha), Orr, N. (Nick), Daley, F. (Frances), Coulson, P. (Penny), Ali, H.R. (Hamid Raza), Blows, F. (Fiona), Benítez, J. (Javier), Milne, R.L. (Roger), Brenner, H. (Hermann), Stegmaier, C. (Christa), Mannermaa, A. (Arto), Chang-Claude, J. (Jenny), Rudolph, A. (Anja), Sinn, P. (Peter), Couch, F.J. (Fergus), Devilee, P. (Peter), Tollenaar, R.A.E.M. (Rob), Seynaeve, C.M. (Caroline), Figueroa, J.D. (Jonine), Sherman, M.E. (Mark), Lissowska, J. (Jolanta), Hewitt, S.M. (Stephen), Eccles, D. (Diana), Hooning, M.J. (Maartje), Hollestelle, A. (Antoinette), Martens, J.W.M. (John), Deurzen, C.H.M. (Carolien) van, Investigators, C.F. (kConFab), Bolla, M.K. (Manjeet K.), Wang, Q. (Qin), Jones, M. (Michael), Schoemaker, M. (Minouk), Wesseling, J. (Jelle), Leeuwen, F.E. (Flora) van, Veer, L.J. (Laura) van 't, Easton, D.F. (Douglas), Swerdlow, A.J. (Anthony ), Dowsett, M. (Mitch), Pharoah, P.D.P. (Paul), Schmidt, M.K. (Marjanka), and García-Closas, M. (Montserrat)

Abstract

Background: The value of KI67 in breast cancer prognostication has been questioned due to concerns on the analytical validity of visual KI67 assessment and methodological limitations of published studies. Here, we investigate the prognostic value of automated KI67 scoring in a large, multicentre study, and compare this with pathologists' visual scores available in a subset of patients. Methods: We utilised 143 tissue microarrays containing 15,313 tumour tissue cores from 8088 breast cancer patients in 10 collaborating studies. A total of 1401 deaths occurred during a median follow-up of 7.5 years. Centralised KI67 assessment was performed using an automated scoring protocol. The relationship of KI67 levels with 10-year breast cancer specific survival (BCSS) was investigated using Kaplan-Meier survival curves and Cox proportional hazard regression models adjusted for known prognostic factors. Results: Patients in the highest quartile of KI67 (>12 % positive KI67 cells) had a worse 10-year BCSS than patients in the lower three quartiles. This association was statistically significant for ER-positive patients (hazard ratio (HR) (95 % CI) at baseline = 1.96 (1.31-2.93); P = 0.001) but not for ER-negative patients (1.23 (0.86-1.77); P = 0.248) (P-heterogeneity = 0.064). In spite of differences in characteristics of the study populations, the estimates of HR were consistent across all studies (P-heterogeneity = 0.941 for ER-positive and P-heterogeneity = 0.866 for ER-negative). Among ER-positive cancers, KI67 was associated with worse prognosis in both node-negative (2.47 (1.16-5.27)) and node-positive (1.74 (1.05-2.86)) tumours (P-heterogeneity = 0.671). Further classification according to ER, PR and HER2 showed statistically significant associations with prognosis among hormone receptor-positive patients regardless of HER2 status (P-heterogeneity = 0.270) and among triple-negative patients (1.70 (1.02-2.84)). Model fit

Published
2016
Full Text
View/download PDF

4. Annexin A1 expression in a pooled breast cancer series: Association with tumor subtypes and prognosis

Author

Sobral-Leite, M. (Marcelo), Wesseling, J. (Jelle), Smit, V.T.H.B.M. (Vincent), Nevanlinna, H. (Heli), van Miltenburg, M.H. (Martine H.), Sanders, J. (Joyce), Hofland, I. (Ingrid), Blows, F. (Fiona), Coulson, P. (Penny), Patrycja, G. (Gazinska), Schellens, J.H.M. (Jan), Fagerholm, R. (Rainer), Heikkilä, P. (Päivi), Aittomäki, K. (Kristiina), Blomqvist, C. (Carl), Provenzano, E. (Elena), Ali, H.R. (Hamid Raza), Figueroa, J.D. (Jonine), Sherman, M.E. (Mark), Lissowska, J. (Jolanta), Mannermaa, A. (Arto), Kataja, V. (Vesa), Kosma, V-M. (Veli-Matti), Hartikainen, J.M. (J.), Phillips, K.-A. (Kelly-Anne), Couch, F.J. (Fergus), Olson, J.E. (Janet), Vachon, C. (Celine), Visscher, D. (Daniel), Brenner, H. (Hermann), Butterbach, K. (Katja), Arndt, V. (Volker), Holleczek, B. (B.), Hooning, M.J. (Maartje), Hollestelle, A. (Antoinette), Martens, J.W.M. (John), Deurzen, C.H.M. (Carolien) van, Van de Water, B. (Bob), Broeks, A. (Annegien), Chang-Claude, J. (Jenny), Chenevix-Trench, G. (Georgia), Easton, D.F. (Douglas), Pharoah, P.D.P. (Paul), García-Closas, M. (Montserrat), de Graauw, M. (Marjo), Schmidt, M.K. (Marjanka), Sobral-Leite, M. (Marcelo), Wesseling, J. (Jelle), Smit, V.T.H.B.M. (Vincent), Nevanlinna, H. (Heli), van Miltenburg, M.H. (Martine H.), Sanders, J. (Joyce), Hofland, I. (Ingrid), Blows, F. (Fiona), Coulson, P. (Penny), Patrycja, G. (Gazinska), Schellens, J.H.M. (Jan), Fagerholm, R. (Rainer), Heikkilä, P. (Päivi), Aittomäki, K. (Kristiina), Blomqvist, C. (Carl), Provenzano, E. (Elena), Ali, H.R. (Hamid Raza), Figueroa, J.D. (Jonine), Sherman, M.E. (Mark), Lissowska, J. (Jolanta), Mannermaa, A. (Arto), Kataja, V. (Vesa), Kosma, V-M. (Veli-Matti), Hartikainen, J.M. (J.), Phillips, K.-A. (Kelly-Anne), Couch, F.J. (Fergus), Olson, J.E. (Janet), Vachon, C. (Celine), Visscher, D. (Daniel), Brenner, H. (Hermann), Butterbach, K. (Katja), Arndt, V. (Volker), Holleczek, B. (B.), Hooning, M.J. (Maartje), Hollestelle, A. (Antoinette), Martens, J.W.M. (John), Deurzen, C.H.M. (Carolien) van, Van de Water, B. (Bob), Broeks, A. (Annegien), Chang-Claude, J. (Jenny), Chenevix-Trench, G. (Georgia), Easton, D.F. (Douglas), Pharoah, P.D.P. (Paul), García-Closas, M. (Montserrat), de Graauw, M. (Marjo), and Schmidt, M.K. (Marjanka)

Abstract

Background: Annexin A1 (ANXA1) is a protein related with the carcinogenesis process and metastasis formation in many tumors. However, little is known about the prognostic value of ANXA1 in breast cancer. The purpose of this study is to evaluate the association between ANXA1 expression, BRCA1/2 germline carriership, specific tumor subtypes and survival in breast cancer patients. Methods: Clinical-pathological information and follow-up data were collected from nine breast cancer studies from the Breast Cancer Association Consortium (BCAC) (n = 5,752) and from one study of familial breast cancer patients with BRCA1/2 mutations (n = 107). ANXA1 expression was scored based on the percentage of immunohistochemical staining in tumor cells. Survival analyses were performed using a multivariable Cox model. Results: The frequency of ANXA1 positive tumors was higher in familial breast cancer patients with BRCA1/2 mutations than in BCAC patients, with 48.6 % versus 12.4 %, respectively; P <0.0001. ANXA1 was also highly expressed in BCAC tumors that were poorly differentiated, triple negative, EGFR-CK5/6 positive or had developed in patients at a young age. In the first 5 years of follow-up, patients with ANXA1 positive tumors had a worse breast cancer-specific survival (BCSS) than ANXA1 negative (HRadj = 1.35; 95 % CI = 1.05-1.73), but the association weakened after 10 years (HRadj = 1.13; 95 % CI = 0.91-1.40). ANXA1 was a significant independent predictor of survival in HER2+ patients (10-years BCSS: HRadj = 1.70; 95 % CI = 1.17-2.45). Conclusions: ANXA1 is overexpressed in familial breast cancer patients with BRCA1/2 mutations and correlated with poor prognosis features: triple negative and poorly differentiated tumors. ANXA1 might be a biomarker candidate for breast cancer survival prediction in high risk groups such as HER2+ cases.

Published
2015
Full Text
View/download PDF

5. Crowdsourcing the General Public for Large Scale Molecular Pathology Studies in Cancer

Author

Candido dos Reis, F.J. (Francisco J.), Lynn, S. (Stuart), Ali, H.R. (Hamid Raza), Eccles, D. (Diana), Hanby, A. (Andrew), Provenzano, E. (Elena), Caldas, C. (Carlos), Howat, W.J. (Will), McDuffus, L.-A. (Leigh-Anne), Liu, B. (Bin), Daley, F. (Frances), Coulson, P. (Penny), Vyas, R.J. (Rupesh J.), Harris, L.M. (Leslie M.), Owens, J.M. (Joanna M.), Carton, A.F.M. (Amy F.M.), McQuillan, J.P. (Janette P.), Paterson, A.M. (Andy M.), Hirji, Z. (Zohra), Christie, S.K. (Sarah K.), Holmes, A.R. (Amber R.), Schmidt, M.K. (Marjanka), García-Closas, M. (Montserrat), Easton, D.F. (Douglas), Bolla, M.K. (Manjeet), Wang, Q. (Qing), Benítez, J. (Javier), Milne, R.L. (Roger L.), Mannermaa, A. (Arto), Couch, F.J. (Fergus), Devilee, P. (Peter), Tollenaar, R.A.E.M. (Rob), Seynaeve, C.M. (Caroline), Cox, A. (Angela), Cross, S.S. (Simon), Blows, F. (Fiona), Sanders, J. (Joyce), de Groot, R. (Renate), Figueroa, J.D. (Jonine), Sherman, M. (Mark), Hooning, M.J. (Maartje), Brenner, H. (Hermann), Holleczek, B. (Bernd), Stegmaier, C. (Christa), Lintott, C. (Chris), Pharoah, P.D.P. (Paul), Candido dos Reis, F.J. (Francisco J.), Lynn, S. (Stuart), Ali, H.R. (Hamid Raza), Eccles, D. (Diana), Hanby, A. (Andrew), Provenzano, E. (Elena), Caldas, C. (Carlos), Howat, W.J. (Will), McDuffus, L.-A. (Leigh-Anne), Liu, B. (Bin), Daley, F. (Frances), Coulson, P. (Penny), Vyas, R.J. (Rupesh J.), Harris, L.M. (Leslie M.), Owens, J.M. (Joanna M.), Carton, A.F.M. (Amy F.M.), McQuillan, J.P. (Janette P.), Paterson, A.M. (Andy M.), Hirji, Z. (Zohra), Christie, S.K. (Sarah K.), Holmes, A.R. (Amber R.), Schmidt, M.K. (Marjanka), García-Closas, M. (Montserrat), Easton, D.F. (Douglas), Bolla, M.K. (Manjeet), Wang, Q. (Qing), Benítez, J. (Javier), Milne, R.L. (Roger L.), Mannermaa, A. (Arto), Couch, F.J. (Fergus), Devilee, P. (Peter), Tollenaar, R.A.E.M. (Rob), Seynaeve, C.M. (Caroline), Cox, A. (Angela), Cross, S.S. (Simon), Blows, F. (Fiona), Sanders, J. (Joyce), de Groot, R. (Renate), Figueroa, J.D. (Jonine), Sherman, M. (Mark), Hooning, M.J. (Maartje), Brenner, H. (Hermann), Holleczek, B. (Bernd), Stegmaier, C. (Christa), Lintott, C. (Chris), and Pharoah, P.D.P. (Paul)

Abstract

Background: Citizen science, scientific research conducted by non-specialists, has the potential to facilitate biomedical research using available large-scale data, however validating the results is challenging. The Cell Slider is a citizen science project that intends to share images from tumors with the general public, enabling them to score tumor markers independently through an internet-based interface. Methods: From October 2012 to June 2014, 98,293 Citizen Scientists accessed the Cell Slider web page and scored 180,172 sub-images derived from images of 12,326 tissue microarray cores labeled for estrogen receptor (ER). We evaluated the accuracy of Citizen Scientist's ER classification, and the association between ER status and prognosis by comparing their test performance against trained pathologists. Findings: The area under ROC curve was 0.95 (95% CI 0.94 to 0.96) for cancer cell identification and 0.97 (95% CI 0.96 to 0.97) for ER status. ER positive tumors scored by Citizen Scientists were associated with survival in a similar way to that scored by trained pathologists. Survival probability at 15. years were 0.78 (95% CI 0.76 to 0.80) for ER-positive and 0.72 (95% CI 0.68 to 0.77) for ER-negative tumors based on Citizen Scientists classification. Based on pathologist classification, survival probability was 0.79 (95% CI 0.77 to 0.81) for ER-positive and 0.71 (95% CI 0.67 to 0.74) for ER-negative tumors. The hazard ratio for death was 0.26 (95% CI 0.18 to 0.37) at diagnosis and became greater than one after 6.5. years of follow-up for ER scored by Citizen Scientists, and 0.24 (95% CI 0.18 to 0.33) at diagnosis increasing thereafter to one after 6.7 (95% CI 4.1 to 10.9) years of follow-up for ER scored by pathologists. Interpretatio

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results